SOPHiA GENETICS SA (SOPH)
After hours:
| Previous close | 4.9700 |
| Open | 5.0500 |
| Bid | 3.6100 x 200 |
| Ask | 5.6900 x 200 |
| Day's range | 4.4301 - 5.0700 |
| 52-week range | 2.1300 - 7.3700 |
| Volume | |
| Avg. volume | 66,657 |
| Market cap | 300.386M |
| Beta (5Y monthly) | 1.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2200 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.67 |
Simply Wall St.SOPHiA GENETICS First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
SOPHiA GENETICS ( NASDAQ:SOPH ) First Quarter 2024 Results Key Financial Results Revenue: US$15.8m (up 13% from 1Q...
ZacksWall Street Analysts Think SOPHiA GENETICS (SOPH) Could Surge 64.95%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 65% in SOPHiA GENETICS (SOPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GlobeNewswireSOPHiA GENETICS Reports First Quarter 2024 Results
Consistent Operational Execution; Robust New Business Momentum; Guidance ReaffirmedBOSTON and ROLLE, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue grew 13% year-over-year to $15.8 million; Constant currency revenue excluding COVID-related revenue grew 12% year-over-yearGross
